If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJp Morg.as Regulatory News (JAGI)

Share Price Information for Jp Morg.as (JAGI)

Share Price is delayed by 15 minutes
Get Live Data
600.00    -18.00 (-2.91%)
Bid:
612.00
Ask:
600.00
Spread: -12.00 (-1.961%)
Market Cap: £403.93m
JAGI Live PriceLast checked at - London Stock Exchange

Intraday Jp Morg.as Share Chart

Initiation from QuotedData

5 Aug 2025 14:04

RNS Number : 0845U
JPMorgan Asia Growth & Income PLC
05 August 2025
 

JPMorgan Asia Growth and Income - Initiation from QuotedData

5th August 2025

Asain income without compromising on growth

JPMorgan Asia Growth and Income (JAGI) has a solid long-term track record of outperformance of its benchmark (the MSCI All Countries Asia ex Japan index), helped by its focus on maximising long-term total returns. In February 2025, the trust introduced an even more enhanced dividend policy, that delivers an attractive level of income without compromising on the manager's ability to pick the best stocks for the portfolio, which should help maintain the trust's long-term capital growth potential.

Considerable effort is being made to moderate the volatility of JAGI's share price discount to NAV with the use of share buybacks, and that appears to be working well. We see scope for increased demand for the trust and potentially a narrowing of the discount as investors come to appreciate the new dividend. The region could also benefit as investors consider reallocating funds from the US to other, faster-growing regions such as Asian markets, many of which exhibit more favourable demographic trends and economic growth prospects.

Full Research:

https://quoteddata.com/research/jpmorgan-asia-growth-and-income-asian-income-without-compromising-on-growth-qd/

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: Marten & Co was paid to produce this note JPMorgan Asian Growth & Income Plc, and it is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the Financial Conduct Authority. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of the Financial Conduct Authority.

QUOTEDDATA50 Gresham Street | London EC2V 7AYTel: +44 (0) 20 3691 9430

www.quoteddata.com | research@quoteddata.com | www.martenandco.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASSLFEIEISEIA
Date   Source Headline
15th Oct 20245:07 pmRNSTransaction in Own Shares
15th Oct 202411:34 amRNSNet Asset Value(s)
14th Oct 20245:17 pmRNSTransaction in Own Shares
14th Oct 202411:27 amRNSGearing announcement
14th Oct 202410:15 amRNSNet Asset Value(s)
11th Oct 20245:10 pmRNSTransaction in Own Shares
11th Oct 202411:28 amRNSNet Asset Value(s)
10th Oct 20245:18 pmRNSTransaction in Own Shares
10th Oct 20242:31 pmRNSTop Ten Largest Investments
10th Oct 202411:42 amRNSNet Asset Value(s)
9th Oct 20245:01 pmRNSTransaction in Own Shares
9th Oct 202411:05 amRNSNet Asset Value(s)
8th Oct 20245:10 pmRNSTransaction in Own Shares
8th Oct 202410:30 amRNSNet Asset Value(s)
7th Oct 20245:20 pmRNSTransaction in Own Shares
7th Oct 202412:27 pmRNSGearing announcement
7th Oct 202411:27 amRNSNet Asset Value(s)
4th Oct 20245:07 pmRNSTransaction in Own Shares
4th Oct 202411:09 amRNSNet Asset Value(s)
3rd Oct 20245:19 pmRNSTransaction in Own Shares
3rd Oct 202411:06 amRNSNet Asset Value(s)
2nd Oct 20245:06 pmRNSTransaction in Own Shares
2nd Oct 202412:22 pmRNSReplacement for RNS number 5346G
2nd Oct 202411:11 amRNSNet Asset Value(s)
1st Oct 20245:10 pmRNSTransaction in Own Shares
1st Oct 20242:19 pmRNSClosed Period Notification
1st Oct 20241:17 pmRNSDividend Declaration
1st Oct 202412:09 pmRNSNet Asset Value(s)
1st Oct 202411:43 amRNSTotal Voting Rights
30th Sep 20245:05 pmRNSTransaction in Own Shares
30th Sep 202412:17 pmRNSGearing Announcement
30th Sep 202411:12 amRNSNet Asset Value(s)
27th Sep 20245:19 pmRNSTransaction in Own Shares
27th Sep 202411:46 amRNSNet Asset Value(s)
26th Sep 20245:17 pmRNSTransaction in Own Shares
26th Sep 202411:16 amRNSNet Asset Value(s)
25th Sep 20245:13 pmRNSTransaction in Own Shares
25th Sep 202410:57 amRNSNet Asset Value(s)
24th Sep 202411:27 amRNSNet Asset Value(s)
23rd Sep 20245:09 pmRNSTransaction in Own Shares
23rd Sep 202411:22 amRNSGearing Announcement
23rd Sep 202410:57 amRNSNet Asset Value(s)
20th Sep 20245:06 pmRNSTransaction in Own Shares
20th Sep 202410:51 amRNSNet Asset Value(s)
19th Sep 20244:59 pmRNSTransaction in Own Shares
19th Sep 202410:38 amRNSNet Asset Value(s)
18th Sep 20245:07 pmRNSTransaction in Own Shares
18th Sep 202410:38 amRNSNet Asset Value(s)
17th Sep 20245:27 pmRNSTransaction in Own Shares
17th Sep 202410:58 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.